Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7223203 | 0.93 | HPGD (0.39) | HPGDKMT2AALDH1A1MEN1LMNA | |
| SCHEMBL7231130 | 0.87 | KMT2A (0.40) | HPGDKMT2AALDH1A1LMNAMAPT | |
| SCHEMBL7229260 | 0.86 | ALDH1A1 (0.38) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL7224270 | 0.83 | NR1I2 (0.46) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL7221678 | 0.82 | CYTH2 (0.56) | HPGDKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7229122 | 0.81 | CYP3A4 (0.42) | KMT2AALDH1A1MEN1MAPTRORC | |
| SCHEMBL7230113 | 0.79 | CYTH2 (0.49) | KMT2AALDH1A1MEN1MAPTHTT | |
| SCHEMBL7229882 | 0.79 | GAA (0.50) | KMT2AALDH1A1MEN1LMNAMAPT | |
| SCHEMBL7221394 | 0.78 | CYP2C9 (0.37) | HPGDKMT2AALDH1A1MEN1LMNA | |
| SCHEMBL8467038 | 0.78 | ALDH1A1 (0.52) | HPGDKMT2AALDH1A1MEN1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | claimed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | claimed |
| EP-0946503-B1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 2002-03-27 | — | — | EP | claimed |
| EP-0946503-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GmbH (DE) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028265-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 1998-07-02 | — | — | WO | claimed |
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | disclosed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | disclosed |
| EP-0946503-B1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 2002-03-27 | — | — | EP | disclosed |
| EP-0946503-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GmbH (DE) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028265-A1 | NITROMETHYLTHIOBENZENE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | MERCK PATENT GMBH (DE) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | AKR1B1, ALDOA, AKR1C1 | HPGD 238/4885KMT2A 4070/4885ALDH1A1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.